Severe drug-induced skin reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis;Schwere arzneimittelinduzierte hautreaktionen. Stevens-Johnson-syndrom und toxisch epidermale nekrolyse

Hautarzt

Volumn 65, Issue 5, 2014, Pages 415-423

  Mockenhaupt, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Blistering; Mortality; Prognosis; Risk factors; Therapy

Indexed keywords

ALLOPURINOL; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE;

ARTICLE; DISEASE SEVERITY; DRUG INDUCED DISEASE; HUMAN; MEDICAL HISTORY; MORTALITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ANAMNESIS; DIFFERENTIAL DIAGNOSIS; PROCEDURES; STEVENS-JOHNSON SYNDROME;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MEDICAL HISTORY TAKING; STEVENS-JOHNSON SYNDROME;

EID: 84902193339     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-013-2694-y     Document Type: Article

References (38)

1. Auquier-Dunant A, Mockenhaupt M, Naldi L et al (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermalnecrolysis. Arch Dermatol 138:1019-1024 (Pubitemid 34875605)
2. Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A pro spective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139:33-36 (Pubitemid 36091571)
3. Bastuji-Garin S, Fouchard N, Bertocchi M et al (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149-153 (Pubitemid 30637181)
4. Bastuji-Garin S, Rzany B, Stern RS et al (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129:92-96 (Pubitemid 23029676)
5. Chronopoulos A, Mockenhaupt M, Pleyer U (2012) Okuläre Beteiligung bei Stevens-Johnson-Syndrom und Toxisch epidermale Nekrolyse. Klin Monatsbl Augenheilkd 229:534-539
6. Chung WH, Hung SI, Yang JY et al (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14:1343-1350
7. Chung WH, Hung SI, Hong HS et al (2004) A marker for Stevens-Johnson syndrome. Nature 428:486
8. Fagot JP, Mockenhaupt M, Bouwes Bavinck JN et al (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis - preliminary results of a case-control study. AIDS 15:1-6
9. Faye O, Roujeau JC (2005) Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIG). Clinical experience to date. Drugs 65(15):2085-2090 (Pubitemid 41475790)
10. Genin E, Chen DP, Hung SI et al (2013) HLA-A*3101 and different types of carbamazepine-induced se vere cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J [Epub ahead of print]
11. Ghislain PD, Roujeau JC (2002) Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndro me. Dermatol Online J 8:5
12. Grosber M, Carsin H, Leclerc F (2006) Epidermal necrolysis in association with mycoplasmapneumoniae infection. Presented at: Meeting on Cut aneous Adverse Drug Reactions and ESDR, Paris, France, 7-9. September 2006. J Invest Dermatol 126:23
13. Haddad C, Sidoroff A, Kardaun SH et al (2013) Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians on the risk? Drug Saf 36:681-686
14. Halevy S, Ghislain PD, Mockenhaupt M et al (2008) Allopurinol is the most common cause of Stevens- Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58: 25-32 (Pubitemid 350298142)
15. Huang YC, Li YC, Chen TJ (2012) The efficacy of in travenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 167:424-432
16. Hung SI, Chung WH, Liou LB et al (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102:4134-4139
17. Kardaun SH, Sekula P, Valeyrie-Allanore L et al (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 169:1071-1080
18. Lipowicz S, Sekula P, Ingen-Housz-Oro S et al (2013) Prognosis of generalized bullous fixed drug eruption: a case control study. Br J Dermatol 168:726-732
19. Liss Y, Mockenhaupt M for the RegiSCAR-study group (2006) Erythema exsudativum multiforme majus versus Stevens-Johnson syndrome: differences in clinical pattern and etiology. Presented at: Meeting on Cutaneous Adverse Drug Reactions and ESDR, Paris, France, 7-9. September 2006. J In vest Dermatol 126:106
20. Liß Y, Mockenhaupt M (2012) Schwere arzneimittelinduzierte Hautreaktionen: Akute generalisier te exanthematische Pustulose und "drug reactions with eosinophilia and systemic symptoms". Allergo J 20:393-405
21. Lonjou C, Thomas L, Borot N et al (2006) A marker for Stevens-Johnson-syndrome and toxic epidermal necrolysis: ethnicity matters. Pharmacogeno mics J 6:265-268 (Pubitemid 44137953)
22. Lonjou C, Borot N, Sekula P et al (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18:99-107
23. Mockenhaupt M (2012) Epidemiologie von kuta nen Arzneimittelreaktionen. Allergologie 35: 131-144
24. Mockenhaupt M, Liß Y (2010) Schwere bullöse arz neimittelinduzierte Hautreaktionen. Akt Dermatol 36:1-12
25. Mockenhaupt M, Idzko M, Grosber M et al (2005) Epidemilogy of staphylococcal scalded skin syndrome in Germany. J Invest Dermatol 124:700-703 (Pubitemid 40489495)
26. Mockenhaupt M (2009) Severe cutaneous adverse reactions. In: Burgdorf WHC, Plewig G, Wolff HH et al (Hrsg) Braun-Falco's dermatology. Springer, Heidelberg, S 473-484
27. Mockenhaupt M, Viboud C, Dunant A et al (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The Euro SCAR-study. J Invest Dermatol 128:35-44 (Pubitemid 350249390)
28. Phillips EJ, Chung WH, Mockenhaupt M et al (2011) Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 127(3 Suppl):S60-S66
29. Pichler WJ, Naisbitt DJ, Park BK (2011) Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol 127(3 Suppl):S74-S81
30. Roujeau JC, Kelly JP, Naldi L et al (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600-1607
31. Rzany B, Hering O, Mockenhaupt M et al (1996) Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Br J Dermatol 135:6-11 (Pubitemid 26225106)
32. Rzany B, Mockenhaupt M, Baur S et al (1996) Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992). Structure and results of a population-based registry. J Clin Epidemiol 49:769-773 (Pubitemid 26280728)
33. Salopek TG (1997) Nikolsky's sign: is it "dry" or is it "wet"? Br J Dermatol 136:762-767
34. Sassolas B, Haddad C, Mockenhaupt M et al (2010) ALDEN an algorithm for assessment of drug causality in Stevens-Johnson-syndrome and toxic epidermal necrolysis. Comparison with case-control analysis. Clin Pharmacol Ther 88:60-68
35. Schneck J, Fagot JP, Sekula P et al (2008) Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58:33-40 (Pubitemid 350298143)
36. Sekula P, Dunant A, Mockenhaupt M et al (2013) Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133:1197-1204
37. Struck MF, Hilbert P, Mockenhaupt M et al (2010) Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med 36:22-32
38. Valeyrie-Allanore L, Wolkenstein P, Brochard L et al (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163:847-853